Phaseline

Companies › Edesa Biotech

Edesa Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EB06
CXCL10 monoclonal antibody
CXCL10Phase 2Non-Segmental Vitiligo (NSV)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07889492EB06Phase 2Non-Segmental Vitiligo (NSV)ImmunologyDec 2027

From the company's SEC filings

Cash of $10m on 2026-06-30; operating cash outflow about $10m a year; runway about 13 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CXCL10 (1)

Companies with the same targets

Changchun GeneScience Pharmaceutical

Companies built like this

Abeona Therapeutics Cabaletta Bio Aravax VivaTech International AltruBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.